ArticleHepatology (Baltimore, Md.)2016
Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.
Article in Hepatology (Baltimore, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Lycorine inhibits migration and proliferation of hepatocellular carcinoma cells by reducing transketonase expression.Journal of Cancer · 2024Article
- Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy.Hepatology forum · 2022Article
- High Expression of SLC41A3 Correlates with Poor Prognosis in Hepatocellular Carcinoma.OncoTargets and therapy · 2021Article
- Article
- High expression of FOXO3 is associated with poor prognosis in patients with hepatocellular carcinoma.Oncology letters · 2020Article
- Article
- Is direct acting antiviral therapy for hepatitis c viral infection associated with increased risk of hepatocellular carcinoma before or after liver transplantation?Hepatobiliary surgery and nutrition · 2019Article
- Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs.Translational cancer research · 2019Review
- Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?Hepatology international · 2019Article
- Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.Liver international : official journal of the International Association for the Study of the Liver · 2018Observational
- Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals.Liver cancer · 2018Article
- Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy.BMC cancer · 2018Article
- Article
- Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.Digestive diseases and sciences · 2017Article
- Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk.Deutsches Arzteblatt international · 2017Article
- Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis.Journal of gastroenterology · 2017Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27136189What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.